Entecavir is an oral antiviral drug with selective activity against hepatitis B virus (HBV). We conducted a randomized, placebo-controlled, dose-escalating study in patients with chronic hepatitis B infection in which we evaluated the efficacy and safety of entecavir given for 28 days. Follow-up was 24 weeks. All doses of entecavir (0.05 mg, 0.1 mg, 0.5 mg, and 1.0 mg) showed a pronounced suppression of replication of the HBV with a 2.21, 2.29, 2.81, and 2.55 mean log10 reduction of viral load, respectively. Approximately 25% of patients on entecavir showed a decline of HBV DNA below the limit of detection of the Chiron HBV-DNA assay (<0.7 MEq/mL). In the postdosing follow-up period patients who were treated with 0.5 and 1.0 mg of entecavir showed a considerably slower return in their HBV DNA levels to baseline compared with those patients treated with lower dosages (P
CITATION STYLE
de Man, R. A., Wolters, L. M. M., Nevens, F., Chua, D., Sherman, M., Lai, C. L., … DeHertogh, D. (2001). Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology, 34(3), 578–582. https://doi.org/10.1053/jhep.2001.26815
Mendeley helps you to discover research relevant for your work.